A third dose of the COVID-19 vaccine could increase protection from COVID-19 for people with cancer, and especially blood cancer, according to a new study from the Francis Crick Institute and The Royal Marsden NHS Foundation Trust published today in Nature Cancer (Wednesday 27 October).

Earlier this year, BRC Clinical Research Fellows Susanna Slater and Justin Mencel attended the 12th annual NIHR Infrastructure Doctoral Research Training Camp hosted by the NIHR Academy.

Men who inherit an increased risk of cancer through ‘Lynch syndrome’ could benefit from regular PSA testing from age 40 to detect early signs of prostate cancer, researchers believe.

An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.

Common gut bacteria can fuel the growth of prostate cancers and allow them to evade the effects of treatment, a new study finds.

Scientists have used artificial intelligence-enhanced tools to successfully propose a new combination of drugs for use against an incurable childhood brain cancer.

Research funded by the NIHR Biomedical Research Centre (BRC) at The Royal Marsden and The Institute of Cancer Research, London (ICR) and pharmaceutical company Kortuc is investigating whether the common antiseptic hydrogen peroxide can enhance the cancer-killing effects of radiotherapy in breast cancer patients.

In June, experts from The Royal Marsden presented the results of their pioneering research to a global online audience at the American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest cancer conference

Combining Immunotherapy with an experimental cancer drug could offer a new way of treating some patients with aggressive brain cancers, according to early results from the Phase 1 Ice-CAP trial, led by researchers from The Institute of Cancer Research, London, and The Royal Marsden.

A pioneering trial to test if men with prostate cancer can safely receive radiotherapy in two large doses rather than smaller doses over five sessions has opened at The Royal Marsden NHS Foundation Trust.